Merck, Pfizer’s Bavencio Misses Ovarian Cancer Trial Endpoints

November 26, 2018 7:45 pm

By Selina McKee

A late-stage study testing Merck KGaA and Pfizer’s PD-L1 antibody Bavencio has failed to meet its primary endpoints in patients with certain forms of ovarian cancer.

The drug was being tested as monotherapy and in combination with … Read more